IL33 and clostridium difficile infection: The robust expression of Areg by all ILCs after IL-33 treatment and the protection of mice from CDI by amphiregulin treatment suggest that the amphiregulin-EGFR pathway is a potential therapeutic target for treating intestinal colitis.